[Hepatocellular carcinoma with tumor thrombi in the portal vein. A comparison of therapeutic effects by different treatments].

Autor:	Cheng SQ; Third Department of Combined Treatment, East Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200438, China. chengshuqun@yahoo.com.cn, Wu MC, Chen H, Shen F, Yang JH, Cong WM, Zhao YX, Wang PJ, Ding GH
Jazyk:	čínština
Zdroj:	Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2005 Mar; Vol. 27 (3), pp. 183-5.
Abstrakt:	Objective: To investigate the effects of different treatments for hepatocellular carcinoma (HCC) with tumor thrombus in the portal vein (PVTT). Methods: From Jan. 2000 to Jan. 2003, a total of 84 HCC patients with PVTT were divided into five groups based on methed of treatment: Group A (n = 9), HCC resection + PVTT removal + postoperative TACE + thymosin alpha(1); Group B (n = 20), HCC resection + PVTT removal + postoperative TACE; Group C (n = 7), HCC resection + PVTT removal; Group D (n = 38), TACE only; Group E (n = 10), conservative treatment only. Results: The rate of PVTT shrinkage or disappearance of groups A, B, C, D and E was 66.7%, 70.0%, 57.1%, 7.9% and 0, respectively with respective median survival time of 10.0, 7.0, 8.0, 5.0 and 2.0 months. The one year survival rate was 44.4%, 15.0%, 14.3%, 10.5% and 0. Conclusion: Resection of HCC and removal of tumor thrombus in the portal vein may have the tumor thrombus cleared in most of the patients and postoperative TACE and thymisin alpha(1) treatment may improve their survival.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu